IP16-16: What Level of Benefit Justifies Beta-3 Agonist Therapy for Overactive Bladder? Estimating the Patient-Perceived Treatment Threshold Using the Smallest Worthwhile Difference Approach

IP16-16: What Level of Benefit Justifies Beta-3 Agonist Therapy for Overactive Bladder? Estimating the Patient-Perceived Treatment Threshold Using the Smallest Worthwhile Difference Approach

Friday, May 15, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)

146C

Abstract

Speakers

Sessions

IP16: Urodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Overactive Bladder

Friday, May 15, 2026 1:00 PM to 3:00 PM

Nirit Rosenblum · NYU

E. Ann Gormley · Professor of Surgery, Geisel School of Medicine, Dartmouth

Elisabeth Sebesta · Vanderbilt University Medical Center

Registered attendees

Atsushi Okada

Associate ProfessorNagoya City University

Log in

See all the content and easy-to-use features by logging in or registering!